COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients

  1. Georg Härter
  2. Christoph D. Spinner
  3. Julia Roider
  4. Markus Bickel
  5. Ivanka Krznaric
  6. Stephan Grunwald
  7. Farhad Schabaz
  8. Daniel Gillor
  9. Nils Postel
  10. Matthias C. Mueller
  11. Markus Müller
  12. Katja Römer
  13. Knud Schewe
  14. Christian Hoffmann

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2020.04.28.20073767: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: Ethics committee approval was obtained from Technical University of Munich (April 4, 2020, Approval No. 194/20s).
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    There is no doubt that our study has important limitations. First, this was a small retrospective and uncontrolled case-series with limited follow-up. All patients were symptomatic, indicating that asymptomatic cases were probably missed. For the antiretroviral treatment regimen, we did not have the precise rates of overall PI or tenofovir prescriptions in the participating centers. Other important data were incomplete, including transmission and exposure conditions. In addition, detailed informations about the onset, duration, intensity of the symptoms, and radiological details of CT scans were limited or not obtained in our retrospective analysis. In conclusion, this preliminary case series does not support an excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir containing ART. Larger studies are needed to elucidate any protective or deleterious effect of HIV and antiretroviral therapy.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1007/s15010-020-01438-z
  3. Version published to 10.1101/2020.04.28.20073767v1 on medRxiv